Idemitsu invests in European Open Innovation Venture Capital Fund from Emerald
Idemitsu Kosan Co.,Ltd. (Headquarters: Tokyo, Japan), has decided to invest in an open innovation evergreen fund, managed by Emerald Technology Ventures, a Swiss clean technology-focused venture capital organization (Headquarters: Zurich, Switzerland). In addition, Idemitsu has decided to establish a new open innovation promotion base in Switzerland. For new business creation, Idemitsu strengthens its efforts to accelerate innovations with start-up companies, not only in Japan, but around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201115005016/en/
The Emerald fund portfolio focuses on industrial innovations in both material chemistry and clean technologies that can help resolve social issues with improvements to energy efficiencies and reductions in carbon dioxide levels. Idemitsu’s investment in this evergreen fund and the creation of a partnership with Emerald will realize new synergies that play on Emerald’s technological expertise and market insight, as well as Emerald’s access to start-up companies in North America, Europe and Israel, together with Idemitsu’s existing technologies and cultivated business networks. Those synergies will in turn lead to the creation of a resilient business portfolio that can flexibly and tenaciously respond to changes in business conditions by incorporating technological innovations from start-up companies.
To further accelerate global open innovations, Idemitsu also plans to establish a European open innovation promotion base in the Swiss canton of Basel-Stadt.
“To resolve the priority themes in our Medium-term Management Plan*, we not only pursue maximal synergies with technologies that are related to those our corporate group has already developed, but will also stress the promotion of open innovations that build on external technologies and ideas,” said Hajime Nakamoto, Managing Executive Officer in Innovation Strategy Planning, Electronic Materials Business, Agri-Bio Business, Lithium Battery Material, Intellectual Property, and Research at Idemitsu. “This investment and the establishment of overseas bases are momentous steps forward for us. Though implementation of open innovation is a long-term objective, we, especially our young employees, drive ourselves forward to laying the foundations early.”
Idemitsu is taking on the challenge of creating new values through the promotion of global open innovation.
Notes:
* Idemitsu’s Medium-term Management Plan (FY2020-2022)
https://sustainability.idemitsu.com/en/themes/259
|
[Overview of Idemitsu Kosan Co.,Ltd.] |
|
|
Company Name |
Idemitsu Kosan Co.,Ltd. |
|
Business Description |
Sustainable supply of various forms of energy and materials |
|
Website |
|
|
[Overview of Emerald Technology Ventures] |
|
|
Company Name |
Emerald Technology Ventures |
|
Business Description |
Open Innovation Venture Capital |
|
Website |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201115005016/en/
Contact information
Public Relations Section, Idemitsu Kosan Co., Ltd.
https://www.idemitsu.com/contact/flow/index.html
Yuuka Sakata (Ms.)
yuka.sakata.1070@idss.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 10:00:00 EET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 09:58:00 EET | Press release
Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019 and 2022, respectively – and reflects increasing investor demand for a specialist global credit platform with expertise across the full spectrum of the asset class. A refreshed logo and new website domain accompany the brand alignment, and from this week Alcentra branded funds start to take on the BSP name.1 Overall, Franklin Templeton’s alternative credit platform – which also includes direct lender Apera – is on track to exceed $100 billion in AUM in 2026. According to new research also published tod
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 09:00:00 EET | Press release
Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Head CP Sourcing at Syngenta. "This tailored approach allows us to make meaningful progress toward our carbon reduction targets for Syngenta AG while m
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 09:00:00 EET | Press release
Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically investing in our future pipeline with a disciplined, long-term approach. We aim to drive sustainable growth and create long-term value for our shareholders, so that we can remain committed to improving patient access worldwide.” Samsung Bioepis Fourth Quarter & Fiscal Year 2025 Results In the fourth quarter of 2025, Samsung Bioepis achieved a
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN ® in Pediatric Spasticity26.1.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom